A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic acid on coronary artery bypass surgery without cardiopulmonary bypass

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 6, 2014, Pages 615-620

  Gurian, Danilo Bortolotto ^a   Meneghini, Adriano ^a   De Abreu, Luiz Carlos ^b   Murad, Neif ^a   De Matos, Leandro Luongo ^a   Pires, Adilson Casemiro ^c   Valenti, Vitor E ^d   Breda, João Roberto ^c  

^a Disciplina de Cardiologia Santo André   (Brazil)

^b Departamento de Morfologia e Fisiologia   (Brazil)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Antifibrinolytics; Bypass; Bypass surgery; Cardiopulmonary; Coronary artery; Coronary artery bypass

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MALE; MIDDLE AGED; PERICARDIUM; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL DRAINAGE; TREATMENT OUTCOME; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; MULTICENTER STUDY; PROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERICARDIUM; PROSPECTIVE STUDIES;

EID: 84906059858     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613476338     Document Type: Article

References (32)

1. Bode AP, Lust RM, Read MS, Fischer TH. Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass. Clin Appl Thromb Hemost. 2008; 14(1):38-54.
2. Untch BR, Jeske WP, Schwartz J, et al. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Clin Appl Thromb Hemost. 2008;14(2):141-148.
3. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980;56(6): 824-834.
4. Souza HJB, Moitinho RF. Strategies to reduce the use of blood products in cardiovascular surgery. Rev Bras Cir Cardiovasc. 2008;23(1):53-59.
5. Tatar H, Ciçek S, Demirkilic U, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg. 1993;55(3):659-661.
6. Depotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994;107(1):271-279.
7. O'Regan DJ, Giannopoulos N, Mediratta N, et al. Topical aprotinin in cardiac operations. Ann Thorac Surg. 1994;58(4):778-781.
8. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-2331.
9. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353-365.
10. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771-783.
11. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358(8):784-793.
12. Ngaage DL, Cale AR, Cowen ME, Griffin S, Guvendik L. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg. 2008;86(4):1195-1202.
13. Pagano D, Howell NJ, Freemantle N, et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg. 2008;135(3):495-502.
14. Breda JR, Gurian DB, Breda AS, et al. Topical use of antifibrinolytic agent to reduce bleeding after coronary artery bypass surgery. Rev Bras Cir Cardiovasc. 2009;24(3):341-345.
15. Hanif M, Nourei SM, Dunning J. Does the use of topical tranexamic acid in cardiac surgery reduce the incidence of post-operative mediatinal bleeding? Interact Cardiovasc Thorac Surg. 2004; 3(4):603-605.
16. De Bonis M, Cavaliere F, Alessandrini F, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000;119(3):575-580.
17. Baric D, Biocina B, Unic D, et al. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg. 2007;31(3): 366-3671.
18. Ciçek S, Tatar H, Demirkiliç U, Kuralay E. Topical use of aprotinin in cardiac surgery. J Thorac Cardiovasc Surg. 1995;110(2): 568-569.
19. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion. 2006;46(3): 327-338.
20. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, 2nd, Haan CK, Hoyston BD. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007; 83(1): S27-S86.
21. Cicek S, Theodoro DA. Topical aprotinin in cardiac operations: a note of caution. Ann Thorac Surg. 1996;61(3):1039-1040.
22. Hosam F, Elsayed E, Daniel B, David L, Lee E. Can local application of Tranexamic acid reduce post-coronary bupass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg. 2009;4(1):25.
23. Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. J Can Anesth. 2009;56(3):202-212.
24. Tatar H, Ciçek S, Demirkilic U, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg. 1993;55(3):659-661.
25. O'Regan DJ, Giannopoulos N, Mediratta N, et al. Topical aprotinin in cardiac operations. Ann Thorac Surg. 1994;58(3): 778-781.
26. Ngaage DL, Bland JM. Lessons from aprotinin: is the use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomized and large matched observational studies. Eur J Cardiothorac Surg. 2010;37(6):1375-1383.
27. Cheng DC, Bainbridge D, Martin JE, Novick RJ. Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology. 2005;102(1):188-203.
28. Abu-Omar Y, Taggart DP. The present status of off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2009;36(2): 312-321.
29. Bainbridge D, Cheng D, Martin J, Novick R. Does off-pump or minimally invasive coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with percutaneous coronary intervention? A meta-analysis of randomized trials. J Thorac Cardiovasc Surg. 2007;133(3):623-631.
30. Parolari A, Alamanni F, Polvani G, et al. Meta-analysis of randomized trials comparing off-pump with on-pump coronary artery graft patency. Ann Thorac Surg. 2005;80(6):2121-2125.
31. Magge MJ, Jablonski KA, Stamou SC, et al. Elimination of cardiopulmonary bypass improves early survival for multivessel coronary artery bypass patients. Ann Thorac Surg. 2002;73(4): 1196-1202.
32. Sabik JF, Gillinov AM, Blackstone EH, et al. Does off-pump coronary surgery reduce morbidity and mortality? J Thorac Cardiovasc Surg. 2002;124(6):698-707.